Dr Agarwals Eye Hospital Ltd (DRAGARWQ)

📊 Quarterly Results (₹ Cr)

Revenue has grown steadily from ₹116 crore in December 2025 to ₹143 crore in June 2026, with operating margins improving from 18% to 22.2% over the same period, indicating operating leverage and successful scaling of higher-margin services. Net profit rose from ₹17 crore to ₹23 crore, and EPS increased from ₹35.76 to ₹48.38, reflecting both volume growth and margin expansion. The upward trend in profitability appears aligned with the rollout of advanced procedures and potential patient acquisition from the new Chennai facility.

🔮 Management Outlook & What's Next

Management has not provided formal forward guidance in the latest filings, but the launch of the Pinhole Pupilloplasty Centre signals strategic investment in specialty expansion. The initiative is framed as a differentiator in a competitive healthcare market, suggesting intent to drive premium service adoption and patient retention. No explicit revenue or margin targets were disclosed, but the move is positioned as a long-term growth enabler.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet shows a stable capital structure with equity remaining flat at ₹5 crore and reserves growing from ₹205 crore to ₹341 crore over two years, indicating retained earnings are being reinvested or accumulated. Borrowings have increased from ₹96 crore to ₹326 crore, suggesting active financing for expansion, likely tied to the new facility or other growth initiatives. Despite higher debt, total assets have risen steadily, supporting the view that capital is being deployed for capacity or service enhancement.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Promoter holding remains stable at 72.67% over the past year, signaling confidence from the founding family. FII ownership has modestly increased from 1.74% to 2.24%, while DII rose from 2.36% to 2.12% with fluctuating public shareholder count. The growing number of shareholders (from 25,449 to 22,954) and stable institutional interest suggest broadening investor acceptance, though foreign participation remains low.

⚖️ Peer Comparison — Healthcare

🔗 Peer Stock Analyses

⚠️ Risk Factors

The company's growth strategy depends on continued innovation and execution in specialty eye care, making it vulnerable to technological obsolescence or regulatory delays in new procedures. Rising borrowings coincide with expansion, increasing financial leverage at a time when margins, while improving, are still being validated at scale. Additionally, the healthcare sector faces execution risks in scaling specialty services across geographies, which could pressure margins if patient acquisition costs rise or reimbursement rates decline.

📋 Recent Filings

• Announcement2026-09-28Dr Agarwals Eye Hospital announced that its trading window will close on September 30, 2026, ahead of the release of unaudited financial results for t…
• 🟡 voting results2026-09-10At the 32nd AGM on September 9, 2026, shareholders approved all six resolutions via remote e-voting and in-person voting, with approval rates exceedin…
• 🟡 Board Meeting2026-09-09Dr Agarwals Eye Hospital held its 32nd AGM on September 9, 2026, via video conference, adopting the audited FY26 financials, declaring a dividend, and…
• 🔴 Announcement2026-08-27Dr Agarwals Eye Hospital launched the world's first dedicated Pinhole Pupilloplasty Centre in Chennai, inaugurated by Tamil Nadu's Chief Minister on A…

🧠 Analyst's Read

Dr Agarwals Eye Hospital is executing a clear growth strategy anchored in innovation and specialty expansion, supported by improving financial trends and a stable ownership base. The key near-term watchpoint is whether the new Pinhole Pupilloplasty Centre drives sustainable revenue and margin accretion, as current results reflect early-stage benefits from this initiative.

Based on filing content and financial data. Not a recommendation.